Although further work is required, the results reveal that it should be possible to develop small‐molecule AspH inhibitors of suitable potency and selectivity for in vivo studies aimed at validating AspH as a medicinal chemistry target to develop novel cancer therapeutics and at exploring the function of EGFD hydroxylation in greater detail. The gene discussed is ASPH; the disease is cancer.